Skip to Content

Bimekizumab – Blocking of Both IL-17A and IL-17F: What Does It Mean for Us Dermatologists and Our patients?

The European Union’s approval of bimekizumab (BIMZELX®) for the treatment of moderate-to-severe plaque psoriasis on August 31st, 2021, has finally been cleared by Norway on November 22nd, 2022, making it the last country in Scandinavia to approve the product.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top